Safety of glucocorticoid dose reduction in microscopic polyangiitis: a multicentre REVEAL cohort study
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf053 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Hirofumi Miyake und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Tenri Hospital, Tenri, Japan. Hauptthemen laut MEDLINE: Glucocorticoids, Microscopic Polyangiitis, Prednisolone. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Objectives
This retrospective, multicentre study evaluated the safety of reducing glucocorticoids (GCs) in patients with microscopic polyangiitis.
Methods
Two hundred twenty-three newly diagnosed microscopic polyangiitis patients, with treatment initiated between 2005 and 2023 in the REVEAL cohort, were divided by 6-month GC dose (≤10 vs. >10 mg/day prednisolone-equivalent). Baseline characteristics were balanced using overlap weighting based on age, sex, disease severity, disease activity, lung/kidney involvement, initial treatment, and year of treatment initiation. Ten-year outcomes were assessed using Cox models, and predictors of GC dose at 6 months were evaluated using logistic regression.
Results
Reducing GCs to ≤10 mg/day at 6 months did not show increased risks of all-cause mortality, infection-related mortality, infections requiring hospitalisation, all relapses, and major relapses. Treatment initiation ≥2020 was linked to GC dose ≤ 10 mg/day at 6 months (odds ratio 5.54, 95% confidence interval 2.78–11.43). Sensitivity analysis (12 mg/day threshold) showed similar results.
Conclusions
Reducing GCs to ≤10 mg/day at 6 months was not linked to increased mortality, infection, or relapse, suggesting it may be a feasible intermediate target. However, more aggressive GC reduction per guidelines might be needed for further infection risk reduction. Individualised tapering with close monitoring remains crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Internal Medicine, Tenri Hospital, Tenri, Japan.
- Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
- Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan.
- Division of Clinical Immunology and Rheumatology, Yodogawa Christian Hospital, Osaka, Japan.
- Department of Clinical Immunology, Osaka Metropolitan University, Graduate School of Medicine, Osaka, Japan.
ORCID-Profile: Hirofumi Miyake, Takuya Kotani
Zitieren
APA
Miyake, H., Kotani, T., Matsuda, S., Okazaki, A., Masuda, Y., Shoji, M., Manabe, A., Kadoba, K., Hiwa, R., Yamamoto, W., Ito, N., Fujiki, Y., Hatta, M., Shiomi, M., Watanabe, R., & Hashimoto, M. (2025). Safety of glucocorticoid dose reduction in microscopic polyangiitis: a multicentre REVEAL cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf053
Vancouver
Miyake H, Kotani T, Matsuda S, Okazaki A, Masuda Y, Shoji M, et al. Safety of glucocorticoid dose reduction in microscopic polyangiitis: a multicentre REVEAL cohort study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf053
BibTeX
@article{Miyake2025,
author = {Miyake, Hirofumi and Kotani, Takuya and Matsuda, Shogo and Okazaki, Ayana and Masuda, Yuichi and Shoji, Mikihito and Manabe, Atsushi and Kadoba, Keiichiro and Hiwa, Ryosuke and Yamamoto, Wataru and Ito, Naoko and Fujiki, Yohei and Hatta, Muneyuki and Shiomi, Mayu and Watanabe, Ryu and Hashimoto, Motomu},
title = {Safety of glucocorticoid dose reduction in microscopic polyangiitis: a multicentre REVEAL cohort study},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf053}
}
EUVIMED